

THERMOGENESIS CORP  
Form 8-K  
February 14, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2014

THERMOGENESIS CORP.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or  
organization)

000-16375  
(Commission File  
Number)

94-3018487  
(I.R.S. Employer  
Identification No.)

2711 Citrus Road  
Rancho Cordova, California 95742  
(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On February 14, 2014, ThermoGenesis Corp. issued a press release announcing its results of operations and financial condition for the quarter ended December 31, 2013. The full text of the press release is set forth in Exhibit 99.1 attached to this report.

This press release includes adjusted EBITDA, which is a financial measure that is not determined in accordance with United States generally accepted accounting principles “U.S. GAAP”. Adjusted EBITDA represents income (loss) from operations excluding amounts for depreciation and amortization, stock-based compensation expense and gain on sale of product line. Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) as a measure of performance. A reconciliation to the comparable GAAP measure is provided in the accompanying financial summaries.

Item 9.01 Financial Statements and Exhibits

99.1 Press release dated February 14, 2014, titled “ThermoGenesis Reports Second Quarter Fiscal Year 2014 Results; Company Obtains Approval for Acquisition of TotipotentRX and Achieves Significant Clinical Milestones.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERMOGENESIS CORP.,  
a Delaware Corporation

Dated: February 14, 2014 /s/ Dan T. Bessey  
Dan. T. Bessey  
Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press release dated February 14, 2014, titled "ThermoGenesis Reports Second Quarter Fiscal Year 2014 Results; Company Obtains Approval for Acquisition of TotipotentRX and Achieves Significant Clinical Milestones."